Citi raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,250 and keeps a Buy rating on the shares. The firm sees Lilly’s “domination” of the weight loss category accelerating following last week’s agreement with the U.S. government for Medicare and Medicaid access. Citi sees an over $40B peak sales opportunity for Lilly’s weight loss treatments and increased 2026 estimates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA appoints Richard Pazdur as Director of CDER
- Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Accelerates
- MeiraGTx price target raised to $30 from $28 at Piper Sandler
- Eli Lilly Stock (LLY) Gets Upgraded as Obesity Drugs Covered by Medicare
- 3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 11/10/2025